ZNF609 and laryngotracheoesophageal cleft: Recently, emerging evidence has demonstrated that circ‐ZNF609 is differentially expressed in distinct cancers, such as RCC, CRC, NPC, GC, LC, HCC, prostate cancer, CC, glioma and other diseases such as RMS, HSCR, vascular dysfunction, glaucoma, CNV, neuropathic pain, DM1, DR and LN.